Loading True North Map…
Avivo Biomedical
Capability profile
Loading True North Map…
Capability profile
Avivo's investigational platform uses enzymes to remove ABO surface sugar markers from blood cells and donor organs. Proposed routes add enzymes to blood-bag collection systems or organ-preservation solutions during perfusion. A type-O-like antigen profile could reduce matching constraints; the published studies test specific parts of that proposition.
In a 2024 study, research-only type-A kidneys declined for transplantation received two Flavonifractor plautii enzymes during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. An ex-vivo ABO-incompatible model showed no anti-A binding or classical complement activation, but lacked coagulation factors and was not a living-recipient transplant.
A separate human-decedent experiment transplanted an enzyme-treated type-A kidney into a type-O brain-dead recipient with high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. From day three, A-antigen regeneration coincided with lesions and complement deposition, leaving persistence and longer-term compatibility unresolved.
The whole-blood study used samples from 16 type-A and four type-O pigs in 45 mL aliquots. At the reported 17.5 micrograms/mL enzyme condition after 15 minutes, A-antigen signal was 0.6% ± 0.2%, close to the type-O control, with stable measured blood-quality parameters. This was laboratory conversion rather than a transfusion experiment.
Kemp Proteins' work addresses enzyme expression, purification and scalable processing. Avivo's federal project includes further preclinical work and planned first-in-human trials, connecting the experimental platform with a funded development programme.
These describe the reviewed application scope, not confirmed deployments, released requirements or procurement eligibility.
Preclinical and process-development stage. Evidence includes ex-vivo kidneys, a short human-decedent kidney experiment and laboratory swine whole blood. The federal project includes planned first-in-human trials; an initiated trial, durable compatibility in living recipients or authorized clinical product is not established.
Research, manufacturing-process and clinical-development collaboration. Proposed blood-bag and organ-perfusion integration remains investigational; no authorized patient-care product is established by the inspected sources.
A technology readiness level is not established by the reviewed public sources.
No reviewed Mission area or released Defence need connection is currently published.
These records support this capability and its published Mission area and Defence need connections. A source count is not a count of independent confirmations.
Avivo Biomedical
Source type: official company product
Supports: Capability · summary
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · maturity
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technology readiness level
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · capability type
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · commercial availability
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technicaldomainslugs
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technicaldomainslugs
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · defence applications
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · core features
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · technical tags
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Supports: Capability · name
The reproduced peer-reviewed kidney abstract describes transplantation of an enzyme-converted type-A kidney into a type-O brain-dead recipient. Hyperacute rejection was absent and no antibody-mediated rejection was seen for two days; lesions and complement deposition appeared from day three alongside A-antigen regeneration. This limited decedent experiment does not demonstrate durable clinical compatibility in living recipients.
Nature Biomedical Engineering · Oct 3, 2025
Source type: official report
Supports: Capability · update child
A converted kidney avoided hyperacute rejection in a type-O brain-dead recipient, but antigen regeneration and immune-mediated signs appeared after the initial two-day period.
Supports: Capability · summary
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Innovation Science and Economic Development Canada
Source type: award or contract
Supports: Capability · maturity
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Supports: Capability · summary
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Kemp Proteins · Jun 2, 2026
Source type: official company news
Supports: Capability · core features
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Capability · commercial availability
Source type: official company product
Supports: Capability · summary
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Public sources cited · Facts and assessments kept separate · Human review
Loading related records…
Supports: Capability · maturity
In a human-decedent experiment, an enzyme-treated type-A kidney was transplanted into a type-O brain-dead recipient with a high anti-A titre. Hyperacute rejection was absent and antibody-mediated rejection was not observed for two days. A-antigen regeneration coincided with lesions and complement deposition from day three. This does not establish durable conversion or efficacy in living recipients; full supplemental protocol was not retrieved.
Supports: Capability · commercial availability
ISED agreement 515732 records a C$10,994,000 contribution to Avivo Biomedical Inc., legal and operating name, for January 1, 2026 to March 31, 2030. The project proposes scaling production, completing preclinical studies and launching first-in-human clinical trials for a dual-use universal blood and organ platform. It lists Vancouver, British Columbia. Payment schedules, milestone conditions and disbursement amounts are not disclosed in the record.
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Capability · summary
Kemp Proteins announced that Avivo selected it for upstream and downstream process optimization, recombinant-protein expression, purification strategy and scalable bioprocessing. Kemp is based in Frederick, Maryland. The release says Avivo is advancing toward first-in-human trials, not that trials have begun or a production process has been qualified.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technicaldomainslugs
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · core features
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technology readiness level
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technicaldomainslugs
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · core features
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · defence applications
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · technical tags
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · capability type
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · name
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Supports: Capability · commercial availability
Avivo describes enzymes that remove surface blood-group markers, with intended conversion of A, B and AB to type O. Proposed integration routes are enzymes added to blood-bag systems at collection for whole blood or red blood cells, and to preservation solutions during organ perfusion. The page says these routes will be integrated; it does not document a cleared clinical product.
Nature Communications · Mar 30, 2024
Source type: official report
Supports: Capability · core features
The 2024 study used research-only type-A kidneys declined for transplant. Two Flavonifractor plautii enzymes, FpGalNAc deacetylase and FpGalactosaminidase, were delivered during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. The ex-vivo ABO-incompatible model did not show anti-A binding or classical complement activation; it lacked coagulation factors and was not a living-recipient transplant.
Supports: Capability · summary
The 2024 study used research-only type-A kidneys declined for transplant. Two Flavonifractor plautii enzymes, FpGalNAc deacetylase and FpGalactosaminidase, were delivered during normothermic or hypothermic machine perfusion. A-antigen levels fell about 80% as early as two hours. The ex-vivo ABO-incompatible model did not show anti-A binding or classical complement activation; it lacked coagulation factors and was not a living-recipient transplant.
Transfusion / PubMed · Dec 24, 2025
Source type: official report
Supports: Capability · summary
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Capability · maturity
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Supports: Capability · core features
The swine whole-blood study used blood from 16 type-A and four type-O pigs, 45 mL aliquots, and two enzymes at different concentrations, temperatures and exposure times. At 17.5 micrograms/mL after 15 minutes, A-antigen signal was 0.6%±0.2%, close to type-O control 0.45%±0.45%. The abstract reports stable laboratory blood-quality measures, including counts, blood gases and clotting tests. It describes laboratory conversion, not in-vivo transfusion or a human clinical product. University, military-academic and Avivo authors participated.
Source type: official report
Supports: Capability · summary
The Transfusion study reports laboratory conversion of type-A swine whole blood toward an O-like antigen profile, with blood-quality measurements comparable to controls under the studied conditions. It is animal-sample evidence, not human transfusion efficacy. Authors disclose Avivo equity and enzyme patents, and the paper expressly disclaims US defence endorsement.
Nature Communications · Mar 30, 2024
Source type: official report
Supports: Capability · update child
Two Flavonifractor plautii enzymes removed approximately 80% of type-A endothelial antigen from human kidneys within two hours under normothermic or hypothermic machine perfusion.
Source type: official company product
Supports: Capability · summary
Kemp Proteins announced selection by Avivo on June 2, 2026 to support upstream/downstream process optimization and enzyme manufacturing development. The collaboration is associated with Avivo's NATO DIANA 2026 participation. It is a manufacturability and scale-up step, not clinical authorization, a licensed blood product or a military supply contract.
Avivo Biomedical
Source type: official company product
Supports: Capability · summary
Avivo develops enzyme-enabled methods intended to convert type-A blood cells and donor organs to universal type O, with public materials describing translational research and potential use in hospital, remote, emergency and trauma settings.